ES2855299T3 - Lípidos oxidados y tratamiento o prevención de la fibrosis - Google Patents

Lípidos oxidados y tratamiento o prevención de la fibrosis Download PDF

Info

Publication number
ES2855299T3
ES2855299T3 ES15863247T ES15863247T ES2855299T3 ES 2855299 T3 ES2855299 T3 ES 2855299T3 ES 15863247 T ES15863247 T ES 15863247T ES 15863247 T ES15863247 T ES 15863247T ES 2855299 T3 ES2855299 T3 ES 2855299T3
Authority
ES
Spain
Prior art keywords
fibrosis
compound
group
use according
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15863247T
Other languages
English (en)
Spanish (es)
Inventor
Itzhak Mendel
Yaniv Salem
Niva Yacov
Eyal Breitbart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Notable Labs Ltd
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Application granted granted Critical
Publication of ES2855299T3 publication Critical patent/ES2855299T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES15863247T 2014-11-26 2015-11-26 Lípidos oxidados y tratamiento o prevención de la fibrosis Active ES2855299T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462085051P 2014-11-26 2014-11-26
PCT/IB2015/059133 WO2016084023A1 (en) 2014-11-26 2015-11-26 Oxidized lipids and treatment or prevention of fibrosis

Publications (1)

Publication Number Publication Date
ES2855299T3 true ES2855299T3 (es) 2021-09-23

Family

ID=56073713

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15863247T Active ES2855299T3 (es) 2014-11-26 2015-11-26 Lípidos oxidados y tratamiento o prevención de la fibrosis

Country Status (8)

Country Link
US (2) US10022388B2 (cg-RX-API-DMAC7.html)
EP (1) EP3223824B1 (cg-RX-API-DMAC7.html)
JP (1) JP6717825B2 (cg-RX-API-DMAC7.html)
CN (1) CN106999506A (cg-RX-API-DMAC7.html)
CA (1) CA2968790A1 (cg-RX-API-DMAC7.html)
ES (1) ES2855299T3 (cg-RX-API-DMAC7.html)
IL (1) IL252509B (cg-RX-API-DMAC7.html)
WO (1) WO2016084023A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
CN106999506A (zh) 2014-11-26 2017-08-01 脉管生物生长有限公司 氧化脂质以及纤维化的治疗或预防
CN113307824B (zh) * 2021-04-26 2022-05-27 浙江大学 一种双亲性材料及其在制备脂质体中的应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5638578B2 (cg-RX-API-DMAC7.html) 1973-05-18 1981-09-08
US4100444A (en) 1975-09-29 1978-07-11 General Electric Company Dynamoelectric machine winding arrangement
US4166132A (en) 1977-08-18 1979-08-28 Pfizer Inc. Antiviral amine derivatives of glycerol and propanediols
GB1572226A (en) 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
CH642665A5 (en) 1979-02-08 1984-04-30 Rudolf Berchtold Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides
US4329302A (en) 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
JPS58154512A (ja) 1982-03-09 1983-09-14 Takeda Chem Ind Ltd 血小板活性化因子抑制剤
JPS5993022A (ja) 1982-11-16 1984-05-29 Kao Corp ポリオ−ルエ−テル化合物およびその製造法ならびにこれを含有する化粧料
DE3307925A1 (de) 1983-03-05 1984-09-06 A. Nattermann & Cie GmbH, 5000 Köln Neue 0-acyl-alkandiol-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4614796A (en) 1983-03-25 1986-09-30 Nippon Shinyaku Co., Ltd. Liposome and method of manufacture therefor
JPS60100544A (ja) 1983-11-08 1985-06-04 Ono Pharmaceut Co Ltd 新規なグリセリン誘導体,その製造方法及びその誘導体を含有する薬剤
JPS60104066A (ja) 1983-11-10 1985-06-08 Ono Pharmaceut Co Ltd グリセリン誘導体
AT383130B (de) 1984-05-15 1987-05-25 Chemie Linz Ag Verfahren zur herstellung von an c1 und c2 verschieden substituierten phosphatidylcholinen und phosphatidylethanolaminen ueber die neuen verbindungen 1-0-tritylglycerophosphocholin beziehungsweise (1-0,n-ditrityl)-glycerophosphoethanolamin
US4710579A (en) 1984-11-09 1987-12-01 Takeda Chemical Industries, Ltd. 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof
JPH0617307B2 (ja) 1984-11-09 1994-03-09 武田薬品工業株式会社 抗腫瘍剤
US4827011A (en) 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
EP0225129B1 (en) 1985-11-29 1989-05-24 Takeda Chemical Industries, Ltd. Phospholipid derivatives, their production and use
US5061626A (en) 1986-03-24 1991-10-29 University Of Sydney Antigenic anarogues of platelet activating factor
EP0299972B1 (en) 1986-04-07 1992-03-04 The Upjohn Company Anthelmintic quaternaryalkyl acylhydrazones, method of use and compositions
JPS6294A (ja) 1986-05-09 1987-01-06 Toyama Chem Co Ltd 新規なグリセロリン酸誘導体およびその塩並びにそれらの製造法
ES2036210T3 (es) 1986-07-14 1993-05-16 Nippon Chemiphar Co., Ltd. Un procedimiento para la preparacion de un derivado de glicerol.
JPS6354386A (ja) 1986-08-26 1988-03-08 Takeda Chem Ind Ltd リン脂質およびその用途
JPS63135395A (ja) 1986-11-28 1988-06-07 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
DE3807123A1 (de) 1988-03-04 1989-09-14 Boehringer Mannheim Gmbh Substrate fuer phospholipasen
JPH01258691A (ja) 1988-04-06 1989-10-16 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
JP2534894B2 (ja) 1988-06-24 1996-09-18 日本ケミファ株式会社 新規なグリセリン誘導体およびその誘導体を含有する血圧降下剤
JPH0248585A (ja) 1988-08-10 1990-02-19 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
CA2001401A1 (en) 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
JPH03258740A (ja) 1990-03-06 1991-11-19 Kao Corp 液体油、その製造法及びこれを含有する化粧料
ES2019552A6 (es) 1990-04-11 1991-06-16 Menarini Lab Procedimiento para la preparacion de glicerofosfolipidos.
JP2869572B2 (ja) 1990-05-14 1999-03-10 和光純薬工業株式会社 ホスファチジルコリン誘導体の製造方法
JPH0754187B2 (ja) 1991-07-31 1995-06-07 株式会社フジマック バッチ型の複合加熱装置
JP3128782B2 (ja) 1992-06-12 2001-01-29 科学技術振興事業団 架橋高分子薄膜の製造方法
US5561052A (en) 1992-06-18 1996-10-01 Koike; Katsumasa Process for detecting oxidized lipids and process for forming oxidized lipids
FR2714382B1 (fr) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
AU1751795A (en) 1994-03-04 1995-09-18 University Of British Columbia, The Liposome compositions and methods for the treatment of atherosclerosis
JP3364313B2 (ja) 1994-03-22 2003-01-08 株式会社トクヤマ ポルフィリン/インジウム錯体及び陰イオン感応膜
JPH0859545A (ja) 1994-08-24 1996-03-05 Kao Corp カルボキシエチルエーテル誘導体及びこれを含有する洗浄剤組成物
AU3216695A (en) 1994-08-29 1996-03-22 University Of North Carolina At Chapel Hill, The Lipid analogs for treating viral infections
JPH08208548A (ja) 1995-02-01 1996-08-13 Kao Corp グリセリン誘導体の製造法
US5660855A (en) 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US6261597B1 (en) 1995-08-31 2001-07-17 Seymour J. Kurtz Method for treating periodontal disease
US6096291A (en) 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
JP3781877B2 (ja) 1997-10-03 2006-05-31 株式会社ムック アスコルビン酸誘導体またはその塩、および医薬
US6414168B1 (en) 1998-12-28 2002-07-02 Caschem, Inc. Epoxidation of ricinic compounds using a phase-transfer catalyst
US6348583B1 (en) 1999-08-30 2002-02-19 Bio-Rad Laboratories, Inc. Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
JP4829454B2 (ja) 1999-11-30 2011-12-07 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 放射線感受性リポソーム
WO2001075168A1 (en) 2000-03-31 2001-10-11 The Regents Of The University Of California Control of a gene induced by oxidized lipids in human artery wall cells
IL156015A0 (en) 2000-11-24 2003-12-23 Vascular Biogenics Ltd Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
DE10155095A1 (de) 2001-11-09 2003-05-22 Cognis Deutschland Gmbh Alkyl(en)ylglycerinethercarbonsäuren
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
NZ553147A (en) 2004-07-09 2010-07-30 Vascular Biogenics Ltd Improved process for the preparation of oxidized phospholipids
US20060194765A1 (en) 2004-11-16 2006-08-31 Garcia Joe G N Methods and compositions using oxidized phospholipids
US8420783B2 (en) 2004-12-08 2013-04-16 Immunomedics, Inc. Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases
WO2007014001A2 (en) 2005-07-21 2007-02-01 The Board Of Trustees Of The Leland Stanford Junior University Multiplex determination of lipid specific binding moieties
WO2007014132A2 (en) 2005-07-22 2007-02-01 Children's Hospital & Research Center At Oakland Hmgcr isoforms in prediction of efficacy and identification of cholesterol-modulating compounds
US20090074720A1 (en) 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US8137977B2 (en) 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
JP2008037763A (ja) 2006-08-01 2008-02-21 Adeka Corp 抗菌剤及び抗菌剤組成物
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
WO2009070298A1 (en) 2007-11-28 2009-06-04 Teva Pharmaceutical Industries, Ltd. Method of delaying the onset of clinically definite multiple sclerosis
US8999960B2 (en) 2008-10-08 2015-04-07 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
KR20110095288A (ko) 2008-11-06 2011-08-24 바스큘라 바이오제닉스 리미티드 산화된 지질 화합물 및 이의 용도
MX342641B (es) 2010-01-05 2016-10-07 Vascular Biogenics Ltd Metodos para uso de un agente adenoviral anti-angiogenico especifico.
MX338931B (es) 2010-01-05 2016-05-06 Vascular Biogenics Ltd Composiciones y metodo para tratar gliobastoma (gbm).
JP2013516455A (ja) 2010-01-05 2013-05-13 バスキュラー バイオジェニックス リミテッド Vb−201を用いた治療
SG11201400208PA (en) 2011-09-01 2014-03-28 Vascular Biogenics Ltd Formulations and dosage forms of oxidized phospholipids
EP2791101B1 (en) * 2011-12-12 2019-09-18 Vascular Biogenics Ltd. Treatment of non-alcoholic steatohepatitis
JP2015510514A (ja) 2012-02-16 2015-04-09 バスキュラー バイオジェニックス リミテッド 乾癬および血管炎症を処置するための方法
CN106999506A (zh) 2014-11-26 2017-08-01 脉管生物生长有限公司 氧化脂质以及纤维化的治疗或预防
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids

Also Published As

Publication number Publication date
WO2016084023A1 (en) 2016-06-02
IL252509B (en) 2020-06-30
JP2017535582A (ja) 2017-11-30
US20180325928A1 (en) 2018-11-15
JP6717825B2 (ja) 2020-07-08
EP3223824A1 (en) 2017-10-04
US10022388B2 (en) 2018-07-17
EP3223824A4 (en) 2018-01-24
CN106999506A (zh) 2017-08-01
CA2968790A1 (en) 2016-06-02
US10206936B2 (en) 2019-02-19
EP3223824B1 (en) 2021-01-06
IL252509A0 (en) 2017-07-31
US20170258818A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
Lipinski et al. Prdx4 limits caspase‐1 activation and restricts inflammasome‐mediated signaling by extracellular vesicles
Zhang et al. 6-Gingerol attenuates macrophages pyroptosis via the inhibition of MAPK signaling pathways and predicts a good prognosis in sepsis
ES2624905T3 (es) Uso de fosfatasa alcalina para la desintoxicación de LPS
Qu et al. Radiotherapy induces intestinal barrier dysfunction by inhibiting autophagy
US20120028921A1 (en) Methods and compositions using oxidized phospholipids
CN104066706A (zh) 炎症的治疗
JP5550906B2 (ja) 嚢胞性疾患の治療のためのプリン誘導体
RU2013105783A (ru) Парентеральные составы производных элацитарабина
US10206936B2 (en) Oxidized lipids and treatment or prevention of fibrosis
Ziegler et al. S1PR3 agonism and S1P lyase inhibition rescue mice in the severe state of experimental sepsis
ES2777533T3 (es) Lípidos oxidados y sus métodos de uso
JP2023106431A (ja) 非アルコール性脂肪性肝疾患と非アルコール性脂肪性肝炎の予防および/または処置に使用するための化合物
US20070078111A1 (en) LPA2 receptor agonist inhibitors of CFTR
ES2990173B2 (es) Complejo de inclusion cuaternario de hidroxitirosol, triptofano, arginina y gluconato de zinc, metodo de obtencion y uso
HK1235296A1 (en) Oxidized lipids and treatment or prevention of fibrosis
Cao et al. Suppression of autoimmune arthritis and neuroinflammation via an amino acid-conjugated butyrate prodrug with enhanced oral bioavailability
Florido Ruiz Study of the mitochondria as a new therapeutic target against head and neck cancer: evaluation of melatonin effects
JP2007106679A (ja) 血液凝固反応促進剤
JP2007091625A (ja) 血液凝固反応促進剤
RU2557906C1 (ru) Фармакологическая композиция для лечения вторичного амилоидоза
WO2007097502A1 (en) Composition for reducing the exudation of serum proteins
Wang et al. The natural compound Notopterol targets JAK2/3 to ameliorate macrophage-induced inflammation and arthritis
Vozenilek Macrophage-Associated Lipin-1 Enzymatic Activity promotes Atherosclerosis
Komalla Liposomes for Treatment of Inflammatory Diseases
OA21266A (en) Dicarboxylic acid esters for inducing an analgesic effect.